Navigation Links
Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
Date:10/30/2007

SAN MATEO, Calif., Oct. 30 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs for chronic and acute diseases, today announced that Donald J. Santel has been appointed to Anthera's Board of Directors.

"Don's experience in transforming early biotech startups into commercial stage organizations will be of benefit as we expand our pipeline and move A-002 into large scale Phase III clinical trials," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "His strategic and operational insights related to the challenges facing development stage companies will be invaluable as Anthera embarks on the next phase of growth."

"We're pleased to have an individual of Don's caliber join our Board of Directors," said Lowell E. Sears Chairman of Anthera's Board of Directors. "We look forward to his contributions that will further shape strategic direction and drive future growth."

Donald J. Santel has 25 years experience in the biotechnology/biopharmaceutical and medical device industries. Most recently, he was Co-Founder and Chief Executive Officer at CoTherix, Inc., where he launched Ventavis(R) Inhalation Solution and led the sale of the company to Actelion Pharmaceuticals, Ltd. in January 2007. Prior to CoTherix, he served as President and Chief Operating Officer of Reflow, and sold the company to Fox Hollow (now EV3) and served as Vice President of Marketing and International Sales at Cardiac Pathways Corporation, a medical device company later acquired by Boston Scientific. Mr. Santel began his career at Medtronic, Inc. Mr. Santel also serves on the board of Hyperion Therapeutics. He has a BSE from Purdue University and an MS in from the University of Minnesota.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately-held pharmaceutical development company committed to world-class development and commercialization of promising clinical products to address the unmet medical needs of patients with life-threatening chronic and acute inflammatory diseases. In 2006, Anthera acquired worldwide rights (except Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase (PLA2) family -- a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienes prostacyclins and other mediators of inflammation. These highly potent compounds inhibit novel upstream steps in the inflammation cascade and have the potential to address a variety of diseases including: acute chest syndrome, acute lung injury, acute respiratory distress syndrome, atherosclerosis, acute coronary syndrome, chronic obstructive pulmonary disease and psoriasis. In order to efficiently commercialize this platform, Anthera has brought together a proven management team with extensive experience in licensing, clinical research, development, and commercialization of anti-inflammatory products. For more information please visit http://www.anthera.com.

Contact:

Anne Bowdidge

(650) 218-6900

pr@anthera.com


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. McDonalds: French Fries, Transparent to more Trans -Fats
2. French fries by McDonalds fries in another controversy
3. Hospital Withdraws McDonalds Reward Scheme
4. Fat Content In McDonald’s & KFCs Foods Varies From Country To Countr
5. McDonald Sets Aside Promises of Healthy Menu
6. Bird flu no threat to McDonalds chicken: Advertisement strategy
7. Hepatitis Scare at McDonald’
8. McDonalds to Start Coffee Chain in Japan
9. Study casts doubt on keyboard ills
10. Who Board To Discuss Asian Tsunami Related Health Issues
11. Abdominal Crunches Not The Best Option For Wash Board Abs.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... MetLoop CEO ... new 2.0 version at the International Roofing Expo in Orlando, Florida on February ... world's most advanced weather technology in the hands of consumers, roofing contractors, manufacturers ...
(Date:2/10/2016)... ... 2016 , ... The Wickman Agency in Garland, TX has ... community. Pledging to select a new beneficiary every 60 days, the agency will ... is to bring community awareness to important local causes by forming campaigns which ...
(Date:2/10/2016)... Tucson, AZ (PRWEB) , ... February 10, 2016 , ... ... prompted the Aging Life Care Association™ (ALCA) to conduct a survey that takes a ... aging experts released today illustrates the prevalence and causes of TBI among the aging ...
(Date:2/10/2016)... ... 10, 2016 , ... Armune BioScience signed a definitive agreement with ... service centers across the country. Launched in April of 2015, Apifiny is the only ... cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Club ... awarded the prestigious Distinguished Emerald Club of the World award, as determined by ... one of the most respected trade publications serving private clubs. , “We’d like ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , February 10, 2016 ... "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market ... Technologies, Participants, and Environment" research report indicates that ... over $149 billion by 2020 growing at a ... of companion diagnostics and targeted therapeutics and is ...
(Date:2/9/2016)... CITY, Calif. , Feb. 9, 2016 /PRNewswire/ - ... device company that is providing innovative evidence-based solutions for ... will release financial results for the fourth quarter and ... February 29, 2016. Company management will host a conference ... Eastern Time) on Monday, February 29, 2016. ...
(Date:2/9/2016)... BILLERICA, Mass. , Feb. 9, 2016  Insulet Corporation ... in tubeless insulin pump technology with its OmniPod ... David A. Lemoine has been appointed to Insulet,s ... comprised of nine directors, eight of whom are independent. ... over 40 years of audit and finance experience and a ...
Breaking Medicine Technology: